![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAS |
Gene summary for FAS |
![]() |
Gene information | Species | Human | Gene symbol | FAS | Gene ID | 355 |
Gene name | Fas cell surface death receptor | |
Gene Alias | ALPS1A | |
Cytomap | 10q23.31 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P25445 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
355 | FAS | LZE4T | Human | Esophagus | ESCC | 9.35e-06 | 1.19e-01 | 0.0811 |
355 | FAS | LZE8T | Human | Esophagus | ESCC | 3.11e-08 | 2.93e-01 | 0.067 |
355 | FAS | LZE20T | Human | Esophagus | ESCC | 1.03e-05 | 3.08e-02 | 0.0662 |
355 | FAS | LZE22D1 | Human | Esophagus | HGIN | 6.30e-06 | 1.15e-01 | 0.0595 |
355 | FAS | LZE22T | Human | Esophagus | ESCC | 4.91e-02 | 2.67e-01 | 0.068 |
355 | FAS | LZE24T | Human | Esophagus | ESCC | 1.64e-11 | 2.72e-02 | 0.0596 |
355 | FAS | LZE6T | Human | Esophagus | ESCC | 3.85e-03 | 2.03e-01 | 0.0845 |
355 | FAS | P2T-E | Human | Esophagus | ESCC | 5.17e-36 | 8.88e-01 | 0.1177 |
355 | FAS | P4T-E | Human | Esophagus | ESCC | 7.55e-04 | 2.05e-02 | 0.1323 |
355 | FAS | P8T-E | Human | Esophagus | ESCC | 1.93e-19 | 2.75e-01 | 0.0889 |
355 | FAS | P9T-E | Human | Esophagus | ESCC | 3.13e-07 | 1.05e-01 | 0.1131 |
355 | FAS | P11T-E | Human | Esophagus | ESCC | 5.71e-06 | 3.92e-01 | 0.1426 |
355 | FAS | P15T-E | Human | Esophagus | ESCC | 2.41e-06 | 6.38e-02 | 0.1149 |
355 | FAS | P16T-E | Human | Esophagus | ESCC | 4.63e-02 | 2.46e-02 | 0.1153 |
355 | FAS | P21T-E | Human | Esophagus | ESCC | 3.15e-05 | 1.90e-01 | 0.1617 |
355 | FAS | P22T-E | Human | Esophagus | ESCC | 1.01e-03 | -2.44e-02 | 0.1236 |
355 | FAS | P23T-E | Human | Esophagus | ESCC | 4.67e-11 | 3.15e-01 | 0.108 |
355 | FAS | P24T-E | Human | Esophagus | ESCC | 4.87e-11 | 1.95e-01 | 0.1287 |
355 | FAS | P26T-E | Human | Esophagus | ESCC | 2.19e-07 | 9.14e-02 | 0.1276 |
355 | FAS | P27T-E | Human | Esophagus | ESCC | 9.86e-04 | 1.08e-01 | 0.1055 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00196938 | Breast | Precancer | ribose phosphate metabolic process | 49/1080 | 396/18723 | 3.81e-07 | 1.78e-05 | 49 |
GO:00091509 | Breast | Precancer | purine ribonucleotide metabolic process | 46/1080 | 368/18723 | 6.47e-07 | 2.71e-05 | 46 |
GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
GO:00092598 | Breast | Precancer | ribonucleotide metabolic process | 47/1080 | 385/18723 | 9.69e-07 | 3.84e-05 | 47 |
GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
GO:00061639 | Breast | Precancer | purine nucleotide metabolic process | 47/1080 | 396/18723 | 2.14e-06 | 7.50e-05 | 47 |
GO:00300999 | Breast | Precancer | myeloid cell differentiation | 45/1080 | 381/18723 | 4.00e-06 | 1.25e-04 | 45 |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00725219 | Breast | Precancer | purine-containing compound metabolic process | 47/1080 | 416/18723 | 8.19e-06 | 2.20e-04 | 47 |
GO:00025737 | Breast | Precancer | myeloid leukocyte differentiation | 27/1080 | 208/18723 | 6.72e-05 | 1.35e-03 | 27 |
GO:00302248 | Breast | Precancer | monocyte differentiation | 9/1080 | 36/18723 | 1.56e-04 | 2.66e-03 | 9 |
GO:19031313 | Breast | Precancer | mononuclear cell differentiation | 43/1080 | 426/18723 | 2.61e-04 | 3.84e-03 | 43 |
GO:00016496 | Breast | Precancer | osteoblast differentiation | 27/1080 | 229/18723 | 3.35e-04 | 4.73e-03 | 27 |
GO:00463946 | Breast | Precancer | carboxylic acid biosynthetic process | 32/1080 | 314/18723 | 1.30e-03 | 1.38e-02 | 32 |
GO:00723304 | Breast | Precancer | monocarboxylic acid biosynthetic process | 24/1080 | 214/18723 | 1.41e-03 | 1.48e-02 | 24 |
GO:00160536 | Breast | Precancer | organic acid biosynthetic process | 32/1080 | 316/18723 | 1.44e-03 | 1.50e-02 | 32 |
GO:00066335 | Breast | Precancer | fatty acid biosynthetic process | 19/1080 | 163/18723 | 2.74e-03 | 2.42e-02 | 19 |
GO:00020649 | Breast | Precancer | epithelial cell development | 23/1080 | 220/18723 | 4.28e-03 | 3.35e-02 | 23 |
GO:00308796 | Breast | Precancer | mammary gland development | 16/1080 | 137/18723 | 5.59e-03 | 4.07e-02 | 16 |
GO:00015036 | Breast | Precancer | ossification | 36/1080 | 408/18723 | 7.53e-03 | 4.98e-02 | 36 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516338 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa0152414 | Esophagus | ESCC | Platinum drug resistance | 56/4205 | 73/8465 | 1.85e-06 | 1.13e-05 | 5.78e-06 | 56 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0514213 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
hsa0493228 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0501028 | Oral cavity | OSCC | Alzheimer disease | 244/3704 | 384/8465 | 1.18e-15 | 3.60e-14 | 1.83e-14 | 244 |
hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa0421018 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa0516418 | Oral cavity | OSCC | Influenza A | 116/3704 | 171/8465 | 1.23e-10 | 1.78e-09 | 9.08e-10 | 116 |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0513030 | Oral cavity | OSCC | Pathogenic Escherichia coli infection | 129/3704 | 197/8465 | 4.32e-10 | 5.17e-09 | 2.63e-09 | 129 |
hsa046689 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa0516729 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
hsa041159 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
hsa0517027 | Oral cavity | OSCC | Human immunodeficiency virus 1 infection | 133/3704 | 212/8465 | 1.42e-08 | 1.40e-07 | 7.12e-08 | 133 |
hsa051608 | Oral cavity | OSCC | Hepatitis C | 103/3704 | 157/8465 | 2.17e-08 | 1.96e-07 | 9.99e-08 | 103 |
hsa0516328 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
FASLG | FAS | FASL_FAS | FASLG | Breast | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Breast | DCIS |
FASLG | FAS | FASL_FAS | FASLG | Cervix | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Cervix | CC |
FASLG | FAS | FASL_FAS | FASLG | Cervix | Healthy |
FASLG | FAS | FASL_FAS | FASLG | Cervix | Precancer |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | AEH |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | EEC |
FASLG | FAS | FASL_FAS | FASLG | HNSCC | OSCC |
FASLG | FAS | FASL_FAS | FASLG | THCA | ADJ |
FASLG | FAS | FASL_FAS | FASLG | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAS | SNV | Missense_Mutation | c.682N>A | p.Asp228Asn | p.D228N | P25445 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | novel | c.783G>T | p.Glu261Asp | p.E261D | P25445 | protein_coding | tolerated(0.24) | benign(0.047) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
FAS | SNV | Missense_Mutation | c.814N>C | p.Glu272Gln | p.E272Q | P25445 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
FAS | SNV | Missense_Mutation | c.628N>T | p.His210Tyr | p.H210Y | P25445 | protein_coding | tolerated(1) | benign(0.119) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
FAS | SNV | Missense_Mutation | c.793G>C | p.Asp265His | p.D265H | P25445 | protein_coding | deleterious(0.02) | benign(0.136) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | rs773565107 | c.340N>A | p.Glu114Lys | p.E114K | P25445 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
FAS | SNV | Missense_Mutation | c.542T>C | p.Leu181Pro | p.L181P | P25445 | protein_coding | tolerated(0.08) | benign(0.055) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | MPA | PROGESTERONE | 14659903 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ALL-TRANS RETINOIC ACID | 9792441 | ||
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VALPROIC ACID | 16328060 | ||
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CHOLECALCIFEROL | CHOLECALCIFEROL | 9811059 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | TENIPOSIDE | TENIPOSIDE | 9543255 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VESNARINONE | VESNARINONE | 9226479 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 11437491 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | LITHIUM | LITHIUM | 15475000 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ASPIRIN | ASPIRIN | 15200494 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | BISPECIFIC ANTIBODY | 11280736 |
Page: 1 2 3 4 |